STOCK TITAN
  1. Home
  2. Sec-filings
  3. CRSP
  4. [Form 4] CRISPR Therapeutics AG Insider Trading Activity

CRISPR Therapeutics (CRSP) CFO option exercises and share sales detailed

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

CRISPR Therapeutics AG’s Chief Financial Officer, Prasad Raju, reported option exercises and share sales in Common Shares. On January 6, 2026, he exercised stock options to acquire 23,361 Common Shares at an exercise price of $45.15 and another 6,339 Common Shares at $44.31. After these transactions, he directly held 30,128 and 36,467 Common Shares, respectively, from the two exercises.

The same day, he reported open-market sales of Common Shares in multiple transactions, including 18,933 shares at a weighted average price of $60.1799 and additional sales at weighted average prices of $60.00 and $60.2134, leaving him with 6,767 Common Shares directly held after the final sale. The filing states these sales were made under a Rule 10b5-1 trading plan adopted on August 18, 2025. The derivative table shows remaining stock options outstanding with expirations in 2033 and vesting schedules described in the footnotes.

Positive

  • None.

Negative

  • None.
Insider Prasad Raju
Role Chief Financial Officer
Sold 29,700 shs ($1.79M)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 23,361 $0.00 --
Exercise Stock Option (Right to Buy) 6,339 $0.00 --
Exercise Common Shares 23,361 $45.15 $1.05M
Exercise Common Shares 6,339 $44.31 $281K
Sale Common Shares 18,933 $60.1799 $1.14M
Sale Common Shares 5,004 $60.00 $300K
Sale Common Shares 5,763 $60.2134 $347K
Holdings After Transaction: Stock Option (Right to Buy) — 76,639 shares (Direct); Common Shares — 30,128 shares (Direct)
Footnotes (1)
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.0000 to $60.7300, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.0000 to $60.4800, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. This option was granted on March 14, 2023 with respect to 100,000 Common Shares, with 25% of the shares vesting on March 14, 2024 and the remaining shares vesting on each monthly anniversary thereafter for a period of 36 months. This option was granted on October 13, 2023 with respect to 13,832 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 13, 2023.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Prasad Raju
(Last) (First) (Middle)
C/O CRISPR THERAPEUTICS
105 WEST FIRST STREET
(Street)
BOSTON MA 02127
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 01/06/2026 M 23,361 A $45.15 30,128 D
Common Shares 01/06/2026 M 6,339 A $44.31 36,467 D
Common Shares 01/06/2026 S(1) 18,933 D $60.1799(2) 17,534 D
Common Shares 01/06/2026 S(1) 5,004 D $60 12,530 D
Common Shares 01/06/2026 S(1) 5,763 D $60.2134(3) 6,767 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $45.15 01/06/2026 M 23,361 (4) 03/14/2033 Common Shares 23,361 $0.00 76,639 D
Stock Option (Right to Buy) $44.31 01/06/2026 M 6,339 (5) 10/13/2033 Common Shares 6,339 $0.00 7,493 D
Explanation of Responses:
1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.0000 to $60.7300, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.0000 to $60.4800, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
4. This option was granted on March 14, 2023 with respect to 100,000 Common Shares, with 25% of the shares vesting on March 14, 2024 and the remaining shares vesting on each monthly anniversary thereafter for a period of 36 months.
5. This option was granted on October 13, 2023 with respect to 13,832 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 13, 2023.
/s/ Elizabeth Ryland Waldinger, attorney-in-fact 01/08/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did CRISPR Therapeutics (CRSP) report in this Form 4?

The Form 4 reports that Chief Financial Officer Prasad Raju exercised stock options to acquire Common Shares and then sold portions of those shares in open-market transactions on January 6, 2026.

How many CRISPR Therapeutics options did the CFO exercise on January 6, 2026?

He exercised stock options covering 23,361 Common Shares at an exercise price of $45.15 and 6,339 Common Shares at $44.31, as shown in the derivative and non-derivative tables.

How many CRISPR Therapeutics shares did the CFO sell, and at what prices?

The Form 4 lists several sales of Common Shares on January 6, 2026, including 18,933 shares at a weighted average price of $60.1799, and additional blocks at weighted average prices of $60.00 and $60.2134, all coded as open-market sales.

Were the CRISPR Therapeutics CFO’s share sales under a Rule 10b5-1 plan?

Yes. A footnote states that the sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

What CRISPR Therapeutics stock options remain outstanding for the CFO after these transactions?

The derivative table shows 76,639 stock options with an exercise price of $45.15 and 7,493 stock options with an exercise price of $44.31 beneficially owned following the reported transactions, all held directly.

What are the vesting terms of the CFO’s CRISPR stock options mentioned in this filing?

One option granted on March 14, 2023 covers 100,000 Common Shares, with 25% vesting on March 14, 2024 and the remainder vesting monthly over 36 months. Another option granted on October 13, 2023 covers 13,832 Common Shares, vesting in 48 equal monthly installments starting November 13, 2023.